Mariana Michel Barbosa
Overview
Explore the profile of Mariana Michel Barbosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muniz R, Camelo R, Araujo M, Barbosa M, Guerra A, de Assis Acurcio F, et al.
Expert Rev Hematol
. 2023 Dec;
16(12):1087-1097.
PMID: 38066708
Background: Emicizumab is a monoclonal antibody approved for prophylaxis against bleeds for people with hemophilia A (PwHA). A systematic review was conducted evaluating the efficacy/effectiveness and the safety of emicizumab...
2.
Camelo R, Barbosa M, Henriques L, Martin A, Godman B, Junior A, et al.
Saudi Pharm J
. 2023 Nov;
31(12):101867.
PMID: 38028212
Costs of hemophilia A treatment are increasing. Waste of clotting products should be avoided. To estimate the first-year waste of emicizumab prophylaxis for people with hemophilia A and inhibitors (PwHAi)...
3.
Souza K, Carrasco G, Rojas-Cortes R, Barbosa M, Bambirra E, Castro J, et al.
PLoS One
. 2023 Oct;
18(10):e0284006.
PMID: 37824507
Objective: To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients with mild to moderate COVID-19 who are at higher risk of developing severe illness, through a systematic review...
4.
Camelo R, Barbosa M, Araujo M, Muniz Jr R, Guerra Jr A, Godman B, et al.
Value Health Reg Issues
. 2022 Dec;
34:31-39.
PMID: 36463835
Objective: This study aimed to measure the cost-effectiveness of prophylaxis with emicizumab in PsHAhri on ITI in Brazil. Methods: A cost-effectiveness modeling analysis was used to estimate the costs per...
5.
Resende L, do Nascimento M, Barbosa M, Rezende C, Pantuzza L, Reis E
Pharmacy (Basel)
. 2022 Nov;
10(6).
PMID: 36412827
Comprehensive medication management (CMM) is the service offered within the clinical practice of pharmaceutical care, which has the objective to optimize pharmacotherapeutic outcomes. Patient satisfaction is a multidimensional construct that...
6.
Moreira T, Alvares-Teodoro J, Barbosa M, Junior A, de Assis Acurcio F
Rev Bras Epidemiol
. 2020 May;
23:e200025.
PMID: 32401914
Introduction: Inappropriate use and increase of health care spending reinforce the need to extend our knowledge about the quality of medication use. Objectives: To describe and evaluate the profile of...
7.
Barbosa M, Garcia M, Nascimento R, Reis E, Junior A, de Assis Acurcio F, et al.
Cien Saude Colet
. 2017 Aug;
22(8):2475-2486.
PMID: 28793065
Objectives: To characterize the infrastructure of public pharmacies in Minas Gerais, comparing municipalities that have received the RFM program to the ones that haven't, in order to verify if the...
8.
Lemos L, Costa J, Machado M, Almeida A, Barbosa M, Kakehasi A, et al.
Rev Bras Reumatol
. 2014 Jul;
54(3):220-30.
PMID: 25054600
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic joint inflammation that often leads to significant disability. Several effective anti-TNF agents have been used, but some patients...
9.
Lemos L, Costa J, Almeida A, Oliveira Junior H, Barbosa M, Kakehasi A, et al.
Rheumatol Int
. 2014 Apr;
34(10):1345-60.
PMID: 24728068
We did a systematic review and meta-analysis on the efficacy and safety of the anti-TNF drugs adalimumab, etanercept, golimumab and infliximab used in psoriatic arthritis (PsA) adult treatment. Additionally, we...
10.
Machado M, Barbosa M, Almeida A, de Araujo V, Kakehasi A, Andrade E, et al.
Rheumatol Int
. 2013 May;
33(9):2199-213.
PMID: 23686218
Biological agents directed against tumor necrosis factor (TNF) represent therapeutic options for patients with ankylosing spondylitis with high disease activity despite use of non-steroidal anti-inflammatory drugs. To evaluate the efficacy...